Sorry, link here: https://www.edisongroup.com/wp-content/uploads/2020/11/Mesoblast-Novartis-licenses-ARDS-program.pdf
At 30 Nov 2020 they reported a valuation for MSB A$4.9bn or A$8.41 per share. I am sure SI has at least this figure in mind knowing we are at an important inflection point with positive OTAT meeting, agvhd approval and way forward with other indications.
New Covid 19 treatment, page-190
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |